Business
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B Financing to accelerate CNS and Immune Disease Drug Development via GAIA Platform
The Series B round saw strong participation from both existing and new investors, demonstrating high industry confidence in Illimis Therapeutics' vision and technology. Eight existing investors, including DSC Investment, Woori Venture Partners, Korea Development Bank, Aju IB Investment, Quad Asset Management, Company K Partners, GS Ventures, and Dayli Partners, reaffirmed their commitment. They were joined by ten new investors: LB Investment, TS Investment, Shinhan Venture Investment, S&S Invest
About this update from Dsc Investment Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"Funds to accelerate Alzheimer's and immune disease drug development, expanding GAIA-based pipeline","length":102,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":267,"olType":false},{"type":"text","content":"SEOUL, South Korea, July 14, 2025 /PRNewswire/ -- The Series B round saw strong participation from both existing and new investors, demonstrating high industry confidence in Illimis Therapeutics' vision and technology. Eight existing investors, including DSC Investment, Woori Venture Partners, Korea Development Bank, Aju IB Investment, Quad Asset Management, Company K Partners, GS Ventures, and Dayli Partners, reaffirmed their commitment. They were joined by ten new investors: LB Investment, TS Investment, Shinhan Venture Investment, S&S Investment, Hana Ventures, Maple Investment Partners, A Ventures, IMM Investment, Schmidt, and Industrial Bank of Korea.","length":677,"tagName":"p"},{"type":"image","alt":"Logo_Illimis Therapeutics","displaySize":"","headline":null,"caption":"Logo_Illimis Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":293,"url":"https://media.zenfs.com/en/prnewswire.com/3df3a11a41b7790e09e13cd5889d6d69"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eN7Qe40O_IM3E4mIiwbMzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTUxNjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/3df3a11a41b7790e09e13cd5889d6d69","width":400,"height":293}},"href":"https://mma.prnewswire.com/media/2730180/Illimis_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The proceeds will be used to accelerate the development of GAIA-based Alzheimer's Disease therapeutics, expand its target indications to various immune disorders, and broaden its pipeline of potential blockbuster drug candidates. The company is actively pursuing early-stage collaborations with global pharmaceutical companies and research institutions to add value to internal programs.","length":391,"tagName":"p"},{"type":"text","content":""In the evolving landscape of new drug development where...